25(OH)-vitamin D and Its Association with Bone Density, Body Composition, Strength, Walking Speed, Physical Performance and Pain in Hospitalized Individuals with Neurological Disorders

The NeuroVitD study aims to assess vitamin D levels in hospitalized cohorts with neurological disorders resulting in motor disabilities, providing epidemiological data necessary for guidelines. The primary objective is to assess vitamin D insufficiency in the neurological populations under investigation and secondary to evaluate the impact of vitamin D supplementation on problems associated with structural and functional parameters.
The NeuroVitD study will be a randomized, cluster, controlled intervention trial lasting 2 years, enrolling 120 individulas, (30 controls), including those with stroke, spinal cord injury, and traumatic brain injury. Comprehensive epidemiological data, including demographic and anthropometric information, will be documented alongside social behaviors such as exercise and smoking. Serum vitamin D levels, bone density, body composition, strength, speed, physical performance and pain will be assessed.
The study will also evaluate the effects of vitamin D supplementation at two distinct dosages: 50,000 I.U of vitamin D weekly for 8 weeks or 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks. Calcium, parathyroid hormone, and phosphorus levels will be assessed to examine the impact of vitamin D administration on additional biochemical markers.
The findings will encompass vitamin D levels, bone density, body composition, strength, walking speed, physical performance and pain. The impact of vitamin D supplementation on various biochemical parameters will be analyzed, along with gender and group comparisons. Correlations will be established based on participants' residential locations, the administration of vitamin D supplementation, seasonal variations, and associations with specific medications for neurological conditions.

Start Date01 Jun 2025

Sponsor / Collaborator-

CTRI/2024/10/075550

/ Not yet recruitingPhase 3IIT

A clinical study to evaluate the efficacy of lakshadi guggulu and Haridra (lakadong turmeric) in improving Vitamin D deficiency in asthikshaya condition of NE region - NA

Start Date03 Mar 2025

Sponsor / Collaborator-

ChiCTR2500096134

/ SuspendedPhase 4IIT

The study on the effect of vitamin D in preventing immune-related adverse reactions in patients with diabetes mellitus

Start Date01 Feb 2025

Sponsor / Collaborator

Changxing County People's Hospital

100 Clinical Results associated with Colecalciferol

100 Translational Medicine associated with Colecalciferol

100 Patents (Medical) associated with Colecalciferol

57,831

Literatures (Medical) associated with Colecalciferol

31 Dec 2025·ANNALS OF MEDICINE

Comparison of effect and mechanism between nalfurafine hydrochloride and narrow-band ultraviolet B phototherapy in the treatment of pruritus in hemodialysis patients

Article

Author: Kim, Jae-Seok ; Choi, Seung Ok ; Yang, Jae Won ; Shin, Dong Hui ; Choi, Eung-Ho ; Lee, Jun Young ; Choi, Sooyeon ; Han, Byoung-Geun ; Kim, Eun Jung

OBJECTIVES:

Pruritus in hemodialysis patients (HDP) is one of the serious complications associated with the quality of life and psychiatric disorder of patients. The narrowband ultraviolet B phototherapy (NB-UVB) treatment showed a statistically significant reduction of itching when performed more than 4 times compared to conservative treatment for itching, and the difference was confirmed to increase with repetition. We aim to compare newly developed Nalfuranfine HCL, kappa-opioid receptor agonist, with NB-UVB in HDP.

METHODS:

Twenty HDP were enrolled from Wonju severance Christian hospital. Visual analog scale (VAS) score, Shiratori score, skin inflammatory cytokine levels, and blood calcium/phosphate/vitamin D levels were measured before four weeks of treatment, during four weeks of treatment, and after four weeks of treatment.

RESULTS:

VAS and Shiratori score was reduced in both nalfurafine and NB-UVB treatment groups significantly. After four weeks of treatment, the NB-UVB treatment group maintained a low Shiratori score, however, the Shiratori score increased in nalfurafine treatment group. Calcium phosphate product concentration was increased in the UVB treatment group and decreased in the nalfurafine treatment group. Vitamin D level was increased only in the UVB treatment group. Skin inflammatory cytokines levels showed a decreasing trend in both groups but not statistically significant. There were no side effects in both treatment groups.

CONCLUSIONS:

Nalfurafine could be an alternative treatment option compared with NB-UVB as an oral medication in pruritis in hemodialysis patients, especially those with hyperphosphatemia.

31 Dec 2025·International Journal of Circumpolar Health

Nutrition biomarker assessment and exploration of the role of country foods to improve food security in the Sahtú Region, Canada

Article

Author: Melo, Larisse ; Phillipps, Breanna ; Bougie, Alyssa ; Jensen, Kirsten ; Ratelle, Mylene ; Andrew, Leon ; Yakeleya, Jessie ; Lamers, Yvonne ; Simmons, Deborah ; Skinner, Kelly ; Laird, Brian

Country foods (i.e. wild traditional food) are associated with improved nutrition for northern populations. In response to community concerns, a project was implemented from 2019 to 2021 in the Sahtú region, Northwest Territories, Canada, to: 1) analyse nutrition biomarkers (vitamins A, B1, B2, B6, B12, D, E, folate, P, Na) in blood samples, in order to assess nutritional status and identify nutrient deficiencies, and 2) use a survey to document how access to country foods may improve food security in the community of Tulı́t'a. Findings from the nutritional biomarker assessments (n = 128) indicated that 94% of participants experienced clinical vitamin D deficiency (<20 ng/L of plasma 25-hydroxy-vitamin D3) and 9% had folate deficiency (<8.7 nmol/L total folate). In the previous 12 months, 71% of participants did not always have money to get more food when needed, but 92% of participants said they were not left hungry. Country foods were used to increase the quality or quantity of the diet. Increasing country food consumption, such as fatty fish and large game meat and organs could mitigate the vitamin D and folate deficiencies. Policies should be implemented to improve food security in the North by facilitating access to country food.

01 Dec 2025·Current Osteoporosis Reports

Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity

Review

Author: Paccou, Julien ; Karam, Léa

Abstract:

Purpose:

This review focuses on recent findi+ngs regarding the management of adverse skeletal effects following weight loss in people living with obesity (PwO). We summarize the guidelines provided by various societies for the prevention and treatment of osteoporosis resulting from bariatric surgery. Next, we discuss the use of traditional antiosteoporosis medications in this population.

Recent Findings:

Guidelines for preventing and treating osteoporosis resulting from bariatric surgery have been recently provided by various societies setting specific treatment criteria for postmenopausal women and men aged ≥ 50 years, based on the occurrence of fragility fractures and/or T-score thresholds. Several studies have highlighted the positive effects of lifestyle changes in preventing high-turnover bone loss; however, data on fracture outcomes are currently unavailable. It is generally accepted that following bariatric procedures, sufficient intake of calcium, vitamin D, and protein, along with regular exercise incorporating progressive, supervised resistance training, is crucial to counteract negative impacts on bone. Regarding the need for medications to combat osteoporosis, most societies recommend zoledronic acid as the preferred choice. This preference is due to the problems associated with oral bisphosphonates, including poor tolerance and absorption issues. Denosumab is typically considered the second choice when bisphosphonates are not suitable or well tolerated. Two randomized controlled studies have recently demonstrated the effectiveness and safety of zoledronic acid and denosumab in addressing high-turnover bone loss.

Summary:

Although guidelines exist for managing skeletal health before and after bariatric surgery, more research is required to validate these recommendations and the use of anti-osteoporosis medications.

142

News (Medical) associated with Colecalciferol

06 Feb 2025

·www.drugs.com

Vitamin D in Early Pregnancy Could Boost Baby's Health

THURSDAY, Feb 6, 2024 -- Getting enough vitamin D, the "sunshine vitamin," during early pregnancy could be important for infant health, new research suggests. Researchers at Penn State found that infants born to women deficient in the nutrient were more likely to be delivered prematurely. Those newborns were also more likely to be smaller compared to babies delivered by women who'd gotten enough of the vitamin in their first trimester. “This study provides evidence that early pregnancy -- and even pre-conception -- nutrition is vitally important,” lead study author Celeste Beck said. She was a doctoral student at Penn State's University Park campus when the study was conducted, and is now an associate research scientist at Heluna Health. “We can't just assume that everybody is deficient, but proper nutrition is something that needs to be on your radar if you may become pregnant," senior study author Alison Gernand , associate professor of nutritional sciences at Penn State, added. “This study provides evidence that vitamin D appears to be an important part of a pregnant woman’s nutritional health," Gernand said. The research appears in the February issue of American Journal of Clinical Nutrition . Vitamin D is considered essential to health, and the body generates it naturally via the absorption of sunlight by the skin. However, many people no longer get enough vitamin D in their daily lives. In fact, prior research has found that “more than 25% of women who are pregnant or lactating have lower than recommended levels of vitamin D,” noted Gernand. “A lot of the development early in pregnancy requires vitamin D, so we conducted this study to better understand how early-pregnancy vitamin D status is related to pregnancy outcomes," she explained in a Penn State news release. Vitamin D insufficiency is defined as blood levels of the nutrient that are below 50 nanomoles per liter (nmol/L) of blood. In the new study, the researchers looked at first trimester vitamin D levels of 351 pregnant U.S. women who'd enrolled in a major federal study between 2010 and 2013. At first, there appeared to be no differences in pregnancy outcomes for women who were either above or below the 50 nmol/L blood level for vitamin D. But concerning differences did arise when researchers looked at a wider range of vitamin D concentrations. As Gerland and Beck reported, women with blood levels lower than 40 nmol/L during their first trimester had rates of preterm birth that were four times that of women who had vitamin D levels of 80 nmol/L or above. What's more, there was a trend to smaller babies (based on fetal length) among women as vitamin D levels during the first trimester decreased. The researchers stressed that these results are preliminary: There were few premature births in the study group overall, so a larger study may be needed to confirm the findings. Vitamin D levels during the second trimester appeared to have no relation to pregnancy outcomes. That could be because vitamin D levels tended to improve among the women later in pregnancy, although more study is needed to understand the finding, the researchers said. The take-home message from the study: Women may need to boost their vitamin D levels early in pregnancy. “Individual women may or may not need supplements depending on their diet and lifestyle," Gerland said. "But healthy nutrition is critical for promoting the healthy development of a fetus. This research indicates that vitamin D levels -- along with iron, folate and other essential nutrients in pregnancy -- should be monitored and understood by obstetricians and women early on to promote healthy birth outcomes.” The study was funded by the U.S. National Institutes of Health, the University of Utah and the Penn State Department of Nutritional Sciences. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

30 Dec 2024

·www.prnewswire.com

2025 Wellness Survey: Sauna Tops Recovery Practices People Want to Try; Building Muscle Remains Top New Year's Fitness Goal in Annual Life Time Poll

When asked about GLP-1 drugs, more than 60% believe the medications can improve overall health CHANHASSEN, Minn., Dec. 30, 2024 /PRNewswire/ -- As 2025 approaches, Life Time (NYSE: LTH) has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. Notable findings include: Continue Reading As 2025 approaches, Life Time has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. When asked which post-workout recovery practices people are interested in trying – or increasing – in 2025: 69.1% of respondents named using a sauna, while 50% said assisted stretching, and 42.4% chose ice baths or cryotherapy. When asked about GLP-1 drugs, 60.8% believe these medications have the potential to improve overall health. A high percentage (74.7%) plan to prioritize their health in 2025, compared to 62.4% of respondents who focused more on their health in 2024. A nearly 20% increase! 99.3% of respondents confirmed they feel happier after completing a workout, reinforcing the mental health benefits of getting your sweat on. For the third consecutive year, building muscle is the top health goal heading into the New Year, followed by eating better, moving more in general and weight loss. Strength training places as the top preferred workout routine, just ahead of cardio-focused workouts. "People of all ages are realizing the benefits of strength training and recovery by making it a priority in their routine," said Danny King, Director of Recovery and Performance at Life Time. "At Life Time, we're continuing to expand the size of our strength training spaces and recovery zones on our exercise floors, prioritizing equipment that fits a variety of body types and doubling down on our digital content. Our free Life Time Digital app is making it easier than ever for people to get started with strength training routines through classes and coaching at their fingertips." Survey respondents addressed 17 questions about their health, exercise habits, workouts and other topics: When it comes to nutrition, over 65% of respondents reported they don't follow a specific nutrition philosophy or eat intuitively. 59.5% of respondents take a supplement daily, with protein powder, multi-vitamins, and vitamin D being the most popular. Of those who take supplements, more than 60% said they take at least two to four daily. On learning about new nutrition and wellness trends, 48.6% prefer guidance from certified professionals, compared to 13% who rely solely on social media. When it comes to fitness apps, people most often use them for workouts, followed by data tracking, nutrition and meditation. More than 80% said they carve out at least several days a week with time dedicated to self-care and activities that make them happy. Unlike the traditional gym or club that is focused on selling and hoping you never use it, Life Time aims to be integral to daily life – a third place – to every member it serves. With more than three decades as a trusted and desirable brand, Life Time is a premier lifestyle, leisure and entertainment company. Regardless of your health and wellness goal in 2025, Life Time an array of programs and services for those 90 days old to 90 years old – from vast strength training floors to Dynamic Personal Training and Dynamic Stretch, to pickleball, tennis, cycle, Pilates, yoga and small-and large-group training, and athletic events you'll find it all here. For those on the go, Life Time also offers a free app with access to on-demand and livestreamed classes, coaching and wellness content from Experience Life magazine. The annual survey was conducted from Dec. 11 to Dec. 23 among general consumers and Life Time members. For more information about Life Time, visit or follow on social media at Facebook, Instagram and LinkedIn. About Life Time Life Time (NYSE: LTH) empowers people to live healthy, happy lives through its portfolio of more than 175 athletic country clubs across the United States and Canada. The health and wellness pioneer also delivers a range of healthy way of life programs and information, and the best curated products and LTH nutritional supplements via its complimentary Life Time Digital app. The Company's healthy living, healthy aging, healthy entertainment communities and ecosystem serve people 90 days to 90+ years old and is supported by a team of more than 41,000 dedicated professionals. In addition to delivering the best programs and experiences through its clubs, Life Time owns and produces nearly 30 of the most iconic athletic events in the country. SOURCE Life Time, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Dec 2024

·www.drugs.com

USPSTF Recommends Against Vitamin D Supplementation for Fracture, Fall Prevention

TUESDAY, Dec. 17, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends against vitamin D supplementation, with or without calcium, for preventing fractures and falls in older adults. These recommendations form the basis of a draft recommendation statement published online Dec. 17. Researchers from the Agency for Healthcare Research and Quality in Rockville, Maryland, reviewed the evidence on supplementation with vitamin D, calcium, or both to prevent fractures and falls in community-dwelling adults. Twenty unique randomized controlled trials were included; eight were conducted exclusively among postmenopausal women and the rest included men (aged 50 years or older) and postmenopausal women. The researchers found that the pooled risk ratio for vitamin D supplementation, with or without calcium, was 0.99 (95 percent confidence interval, 0.86 to 1.13) compared with control, corresponding to an absolute risk difference of zero fewer hip fractures per 1,000 supplemented. For incidence of one or more falls, the pooled relative risk for vitamin D supplementation, with or without calcium, was 0.99 versus control (95 percent confidence interval, 0.97 to 1.01), corresponding to an absolute risk difference of five fewer participants with one or more falls per 1,000 supplemented. Based on these findings, the USPSTF recommends against supplementation with vitamin D, with or without calcium, for the primary prevention of fractures or falls in community-dwelling postmenopausal women and men 60 years or older (D recommendation). The draft recommendation statement and evidence review have been posted for public comment. Comments can be submitted from Dec. 17, 2024, through Jan. 21, 2025. Draft Evidence Review Draft Recommendation Statement Comment on Recommendation Statement Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Colecalciferol

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	CN	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Familial Hypophosphatemic Rickets	CA	-	01 Jan 1985
Hypoparathyroidism	CA	-	01 Jan 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Insulin Resistance	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Overweight	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Polycystic Ovary Syndrome	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Osteoporosis, Postmenopausal	Phase 3	KR	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	IT	Abiogen Pharma SpA	01 Nov 2011
Hypercalcemia	Phase 3	DK	University of Aarhus	01 May 2008
Hyperparathyroidism, Primary	Phase 3	DK	University of Aarhus	01 May 2008
Crohn Disease	Phase 3	DK	University of Aarhus	01 Sep 2005
Lower urinary tract infectious disease	Phase 2	CN	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Osteoporosis	Phase 2	DK	University of Aarhus	01 Dec 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01748448 (ViDMe, CTgov)	Phase 3	Melanoma, Cutaneous Malignant	436	Vitamin D (Vitamin D)	ptlyapxlgh(aazincqevk) = hfzowombpj mejqqxtkzh (tcyjvxemnp, swpofxeunv - gmumtwvtmr) View more	-	17 Feb 2025
				Placebo: Oil (Placebo: Oil)	ptlyapxlgh(aazincqevk) = omigvwabvi mejqqxtkzh (tcyjvxemnp, qnalnekaoy - rjjmotmpdw) View more
NCT01443728 (CTgov)	Phase 2	Asthma \| Vitamin D Deficiency \| Acute Chest Syndrome ... View more	70	Experimental: Vitamin D3 100,000 IU (Vitamin D3 100,000 IU)	fhxreizeof(xkhlidildb) = rkqwrkdrkj mcoyuaukzn (inrjpnkljb, jpdayqufob - izbiozzjsu) View more	-	09 Aug 2024
				Active Comparator: Vitamin D3 12,000 IU (Vitamin D3 12,000 IU)	fhxreizeof(xkhlidildb) = vzjyvelsaq mcoyuaukzn (inrjpnkljb, xqyrcvwidn - iwbxqleinb) View more
625-P (ADA2024)	Not Applicable	Diabetes Mellitus, Type 2 Vitamin D \| Thyroid function	730	Vitamin D (Lower VD group)	itrvfxbcpq(bnbpaupbev) = ihgcswlcjg zjiqfcncdq (zlujsyidtb ) View more	Positive	14 Jun 2024
				Vitamin D (Higher VD group)	itrvfxbcpq(bnbpaupbev) = vrheviikhw zjiqfcncdq (zlujsyidtb ) View more
EULAR2024	Not Applicable	Systemic Lupus Erythematosus	-	Vitamin D (SLE Female Patients)	ccogbsiydr(qvmaoytddd) = rxcrkltdci fukvwhwpfm (pvibfaqabc )	-	05 Jun 2024
				Vitamin D (Control Group)	ccogbsiydr(qvmaoytddd) = jjvbtbjfam fukvwhwpfm (pvibfaqabc )
EULAR2024	Not Applicable	Fibromyalgia Vitamin D levels	-	Vitamin D (Fibromyalgia Syndrome (FMS) patients)	upujiflnax(lultbpufzc) = obyvfisngw iogukowkse (vjoadtwwlu )	Positive	05 Jun 2024
				Vitamin D (Healthy individuals)	upujiflnax(lultbpufzc) = uwzsdlobii iogukowkse (vjoadtwwlu )
ENDO2024	Not Applicable	Osteoporotic Fractures VDD \| serum 25OHD	-	vitamin D (Patients with hip fragility fractures)	oituelivwh(tfqpgebpcj) = snvwwodwke sqkeauctwi (dhvfgtmpik )	-	01 Jun 2024
NCT01169259 (VITAL, ENDO2024)	Phase 3	Diabetes Mellitus, Type 2	-	Vitamin D 2000 IU/d	lcjfqhgyji(awdauwbrfn) = bfysifccyf bnsoydjobt (tzlqndjwqh )	Negative	01 Jun 2024
				Vitamin D (Placebo)	lcjfqhgyji(awdauwbrfn) = wgyyxpqpin bnsoydjobt (tzlqndjwqh )
NCT01169259 (VITAL, ENDO2024)	Phase 3	Diabetes Mellitus, Type 2	-	Vitamin D 2000 IU/d	iflfviuppm(ndpnhtsykf) = mdloatlrrk gzyytqslwe (sibcehxmhw )	Negative	01 Jun 2024
				Vitamin D (Placebo)	iflfviuppm(ndpnhtsykf) = zfwtbqvwbb gzyytqslwe (sibcehxmhw )
ENDO2024	Not Applicable	Hypoparathyroidism	-	Vitamin D supplementation	ivwwjogcfh(nqvnfuetqh) = osyovbnuii gbosaqyepk (grpshtbsza )	-	01 Jun 2024
ENDO2024	Not Applicable	Hyperparathyroidism, Primary 1,25(OH)2 vitamin D \| FGF23	-	Vitamin D (PHPT patients)	vrjchdnyip(vlxuwidnxh) = yypeyysfcb ruiolpnklw (wcytgbxyag ) View more	-	01 Jun 2024
				Vitamin D (Healthy individuals (CTRL))	vrjchdnyip(vlxuwidnxh) = ysvmotzvdt ruiolpnklw (wcytgbxyag ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Colecalciferol

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation